CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Updates in the Management of Primary Mediastinal B Cell Lymphoma.
Updates in the Management of Primary Mediastinal B Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
原发性纵隔大B细胞淋巴瘤（PMBCL）根据世界卫生组织淋巴系统肿瘤分类被视为一种独立病理类型。在蒽环类化疗中加入利妥昔单抗后，患者预后得到改善。剂量调整的R-EPOCH获批后，巩固放疗的作用仍有争议，是否放疗通常依据治疗结束时的PET-CT结果决定。对于复发/难治性疾病，已获批新药及其他在研药物改善了患者结局。本文综述PMBCL初治及复发/难治情境下的不同治疗方式。
Primary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy.
The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under investigation have improved patient outcomes. This review summarizes the different treatment modalities in (PMBCL) in the frontline and the relapsed/refractory settings.
MEMBER ACCOUNT
登录成功会直接打开下一页。
